Summary
To examine whether diabetes affects the ability of β-blockade to suppress adrenaline-stimulated hepatic glucose production, we infused adrenaline with and without propranolol into normal subjects and diabetic patients receiving a constant insulin infusion in basal amounts. In normal subjects, propranolol did not block the transient 50%–60% rise in glucose production during adrenaline infusion. In contrast, propranolol virtually abolished adrenaline-induced hyperglycaemia and glucose production was virtually abolished by propranolol in the diabetic patients, even though they demonstrated an exaggerated response to adrenaline alone (persistent increase in glucose production of 50%–90% above baseline). When insulin was infused together with adrenaline and propranolol in normal subjects in doses exceeding those given to the diabetics (plasma insulin rose threefold), the rise in glucose production was still threefold greater than in the diabetic patients (p<0.02). We conclude that β-blockade is more effective in suppressing the hepatic response to adrenaline in diabetics than in normal subjects. Our data may explain why diabetic subjects are more vulnerable to hypoglycaemia during treatment with propranolol.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Rizza R, Haymond M, Cryer P, Gerich J (1980) Differential effects of epinephrine on glucose production and disposal in man. Am J Physiol 237: E 356-E 362
Shamoon H, Hendler R, Sherwin RS (1980) Altered responsiveness to cortisol, epinephrine and glucagon in insulin-infused juvenile-onset diabetics. A mechanism for diabetic instability. Diabetes 29: 284–291
Exton JH (1980) Mechanisms involved in α-adrenergic phenomena: Role of calcium ions in actions of catecholamines in liver and other tissues. Am J Physiol 238 (Endocrinol Metab 1): E 3-E 12
Sutherland EW, Rall TW (1960) Relation of adenosine 3′-5′ phosphate and phosphorylase to the actions of catecholamines and other hormones. Pharmacol Rev 12: 265–299
Rizza RA, Cryer PE, Haymond MW, Gerich JE (1980) Adrenergic mechanisms for the effects of epinephrine on glucose production and clearance in man. J Clin Invest 65: 632–689
Deibert DC, DeFronzo RA (1980) Epinephrine-induced insulin resistance in man. J Clin Invest 65: 717–721
Rizza RA, Haymond MW, Miles JM, Verdonk GA, Cryer PE, Gerich JE (1980) Effect of α-adrenergic stimulation and its blockade on glucose turnover in man. Am J Physiol (Endocrinol Metab 1): E 467–E 472
Raveno WS, Rosenbaum H (1968) Propranolol and hypoglycaemia. Lancet 1: 920 (Letter)
Kotler MN, Berman L, Rubenstein AH (1966) Hypoglycaemia precipitated by propranolol. Lancet 2: 1389–1390
McAllister Jr RS (1976) Intravenous propranolol administration. A method for rapidly achieving and sustaining desired plasma levels. Clin Pharmacol Ther 20: 517–518
Shamoon H, Sherwin RS (1980) Epinephrine-induced hypoaminoacidemia in normal and diabetic humans: a β-adrenergic effect. Diabetes 29: 875–881
Sherwin RS, Kramer KJ, Tobin JD, Insel PA, Liljenquist JE, Berman M, Andres R (1974) A model of the kinetics of insulin in man. J Clin Invest 53: 1481–1492
Passon PG, Peuler JD (1973) A simplified radiometric assay for plasma norepinephrine and epinephrine. Anal Biochem 51: 618–631
Hales CN, Randle PJ (1963) Immunoassay of insulin with insulin antibody precipitate. Biochem J 88: 137–146
Novak N (1965) Colorimetric ultramicro method for the determination of free fatty acids. J Lipid Res 6: 431–440
Wise JK, Hendler R, Felig P (1973) Influence of glucocorticoids on glucagon secretion and plasma amino acid concentrations in man. J Clin Invest 52: 2774–2782
Sacca L, Sherwin RS, Hendler R, Felig P (1979) Influence of continuous physiologic hyperinsulinemia in glucose kinetics and counterregulatory hormones in normal and diabetic humans. J Clin Invest 63: 849–857
Heding LG (1975) Radioimmunological determination of human C-peptide in serum. Diabetologia 11: 541–548
Steele R (1959) Influences of glucose loading and of injected insulin on hepatic glucose output. Ann NY Acad Sci 82: 420–430
Eigler N, Sacca L, Sherwin RS (1979) Synergistic interactions of physiologic increments of glucagon, epinephrine and cortisol in the dog. A model for stress-induced hyperglycaemia. J Clin Invest 63: 114–123
Cowan JS, Hetenyi Jr G (1971) Glucoregulatory responses in normal and diabetic dogs recorded by a new tracer method. Metab Clin Exp 20: 360–372
Radziuk J, Norwich KH, Vranic M (1978) Experimental validation of measurements of glucose turnover in non-steady state. Am J Physiol 234: E 84-E 93
Snedecor GW, Cochran WG (1967) Statistical methods, 6th edn. Iowa State University Press, Ames, Iowa, pp 93–119, 299–338
Gerich JE, Lorenzi M, Tsalikian E, Karam JH (1976) Studies on the mechanism of epinephrine-induced hyperglycaemia in man: Evidence for participation of pancreatic glucagon secretion. Diabetes 25: 65–71
Sacca L, Hendler R, Sherwin RS (1978) Hyperglycaemia inhibits glucose production in man independent of changes in glucoregulatory hormones. J Clin Endocrinol Metab 47: 1160–1163
DeFronzo RA, Hendler R, Simonson D (1982) Insulin resistance is a prominent feature of insulin-dependent diabetes. Diabetes 31: 795–801
Felig P, Gusberg R, Hendler R, Gump FE, Kinney JM (1974) Concentrations of glucagon and the insulin glucagon ratio in the portal and peripheral circulation. Proc Soc Exp Biol Med 147: 88–90
Horwitz DL, Starr JI, Mako ME, Blackard WE, Rubenstein AH (1975) Proinsulin, insulin and C-peptide concentrations in human portal and peripheral blood. J Clin Invest 55: 1278–1289
Nickerson M, Kunos G (1977) Discussion of evidence regarding induced changes in adrenoceptors. Fed Proc 36: 2580–2583
Williams LT, Lefkowitz RJ, Watanabe AM, Hathaway DR, Besch Jr HR (1977) Thyroid hormone regulation of β-adrenergic receptor number. J Biol Chem 252: 2787–2789
Kunos G (1977) Thyroid hormone-dependent interconversion of myocardial α-adrenoceptors in the rat. Br J Pharmacol 59: 177–189
Olansky L, Jacobsson B, Pohl S (1981) Down regulation of β-adrenergic receptors by insulin in 3T3-L1 adipocytes. Clin Res 29: 871 A
Clarke WL, Santiago JV, Thomas L, Ben-Galim E, Haymond MW, Cryer PE (1978) Adrenergic mechanisms in recovery from hypoglycemia in man: adrenergic blockade, Am J Physiol 5: E 147-E 152
Gerich JE, Langlois M, Noacco C, Karam JH, Forsham PH (1973) Lack of glucagon response to hypoglycemia in diabetes: evidence for an intrinsic pancreatic α cell defect. Science 182: 171–173
Popp D, Shah S, Cryer P (1982) Role of epinephrine-mediated β-adrenergic mechanisms in hypoglycemic glucose counterregulation in insulin-dependent diabetes mellitus. J Clin Invest 69: 315–326
Kleinbaum J, Shamoon H (1983) Impaired counterregulation of hypoglycemia in insulin-dependent diabetes mellitus. Diabetes 32: 493–498
Viberti GC, Keen H, Bloom SR (1980) β Blockade and diabetes mellitus: Effect of oxprenolol and metoprolol on the metabolic, cardiovascular and hormonal response to insulin-induced hypoglycemia in insulin-dependent diabetics. Metabolism 29: 873–879
Simonson D, Sherwin R, DeFronzo R (1981) Adrenergic blockade alters glucose kinetics in diabetics during exercise. Diabetes 39 [Suppl] 1: 11 A
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Shamoon, H., Sherwin, R. β-Adrenergic blockade is more effective in suppressing adrenaline-induced glucose production in Type 1 (insulin-dependent) diabetes. Diabetologia 26, 183–189 (1984). https://doi.org/10.1007/BF00252404
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00252404